Sugi Predict

Sugi Predict / Compounds / SCHEMBL146973

SCHEMBL146973

SCHEMBL146973

FC(F)(F)Cc1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 2/20 0.52
▸ HRH1 P35367 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ LIN28A Q9H9Z2 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ GRIN2D O15399 1/20 0.46
▸ GRIN3B O60391 1/20 0.46
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2A Q12879 1/20 0.46
▸ GRIN2B Q13224 1/20 0.46
▸ GRIN2C Q14957 1/20 0.46
▸ GRIN3A Q8TCU5 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ PTPRA P18433 1/20 0.44
▸ MAOA P21397 2/20 0.44
▸ MAOB P27338 2/20 0.44
▸ HRH3 Q9Y5N1 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31028455 1.00 FDPS (0.52) FDPSHRH1SMN1; SMN2MAPTLIN28A
SCHEMBL2375172 0.83 FDPS (0.49) FDPSHRH1SMN1; SMN2MAPTLIN28A
SCHEMBL27337717 0.79 FDPS (0.46) FDPSHRH1SMN1; SMN2MAPTLIN28A
SCHEMBL15164743 0.79 FDPS (0.46) FDPSHRH1SMN1; SMN2MAPTLIN28A
SCHEMBL29299439 0.79 FDPS (0.46) FDPSHRH1SMN1; SMN2MAPTLIN28A
SCHEMBL13966688 0.79 FDPS (0.53) FDPSHRH1SMN1; SMN2MAPTLIN28A
SCHEMBL2750755 0.78 HRH1 (0.55) HRH1SMN1; SMN2MAPTLIN28ATDP1
SCHEMBL31312939 0.77 HRH1 (0.54) FDPSHRH1SMN1; SMN2MAPTLIN28A
SCHEMBL231091 0.77 FDPS (0.56) FDPSHRH1SMN1; SMN2MAPTLIN28A
SCHEMBL6175608 0.77 FDPS (0.52) FDPSHRH1SMN1; SMN2MAPTLIN28A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2532663-B1 Naphthalenetetracarboxylic acid derivatives and their use as semiconductors BASF SE (DE) 2016-03-16 — — EP claimed
EP-2532663-A1 Naphthalenecarboxylic acid derivatives and their use as semiconductors BASF SE (DE) 2012-12-12 — — EP claimed
US-8283357-B2 Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-10-09 — — US claimed
US-20100311794-A1 CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-12-09 — — US claimed
EP-1891074-A1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS Brystol-Myers Squibb Company (US) 2008-02-27 — — EP claimed
WO-2006138682-A1 AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-12-28 — — WO claimed
US-6429117-B1 Method to create copper traps by modifying treatment on the dielectrics surface CHARTERED SEMICONDUCTOR MANUFACTURING LTD. (SG) 2002-08-06 — — US claimed
EP-4318630-B1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY ASAHI CHEMICAL IND (JP) 2025-10-22 — — EP disclosed
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-01-14 — — US disclosed
EP-4415105-A2 NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE Asahi Kasei Kabushiki Kaisha (JP) 2024-08-14 — — EP disclosed
US-20240178452-A1 Nonaqueous Electrolyte Solution and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-05-30 — — US disclosed
EP-4318630-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY Asahi Kasei Kabushiki Kaisha (JP) 2024-02-07 — — EP disclosed
WO-2022203072-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY 旭化成株式会社 2022-09-29 — — WO disclosed
US-20050085506-A1 Novel gamma secretase inhibitors SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. 2005-04-21 — — US disclosed
WO-2005028440-A1 NOVEL GAMMA SECRETASE INHIBITORS SCHERING CORPORATION (US) 2005-03-31 — — WO disclosed
EP-1472223-A1 GAMMA SECRETASE INHIBITORS SCHERING CORPORATION (US) 2004-11-03 — — EP disclosed
US-20040171614-A1 Novel gamma secretase inhibitors SCHERING-PLOUGH CORPORATION 2004-09-02 — — US disclosed
US-20040048848-A1 Novel gamma secretase inhibitors SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. 2004-03-11 — — US disclosed
WO-2003066592-A1 GAMMA SECRETASE INHIBITORS SCHERING CORPORATION (US) 2003-08-14 — — WO disclosed
US-6429117-B1 Method to create copper traps by modifying treatment on the dielectrics surface CHARTERED SEMICONDUCTOR MANUFACTURING LTD. (SG) 2002-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171614-A1 Novel gamma secretase inhibitors BACE1, BACE2, APP FDPS 4416/4885HRH1 1069/4885SMN1; SMN2 3205/4885
US-20040048848-A1 Novel gamma secretase inhibitors BACE1, BACE2, PSEN1 FDPS 3297/4885HRH1 790/4885SMN1; SMN2 3050/4885
US-20100311794-A1 CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS HDAC1, HDAC5, HDAC3 FDPS 4176/4885HRH1 552/4885SMN1; SMN2 3288/4885
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte CLK2, TYK2, CLK3 FDPS 4873/4885HRH1 4396/4885SMN1; SMN2 1388/4885
US-20050085506-A1 Novel gamma secretase inhibitors BACE1, BACE2, APP FDPS 4185/4885HRH1 780/4885SMN1; SMN2 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.